Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1966 1
1967 2
1969 1
1971 2
1974 1
1988 1
1994 1
1996 4
1997 2
1998 3
1999 1
2000 2
2001 3
2002 2
2003 2
2004 3
2005 10
2006 5
2007 11
2008 14
2009 17
2010 15
2011 15
2012 14
2013 17
2014 14
2015 10
2016 8
2017 20
2018 17
2019 21
2020 18
2021 30
2022 19
2023 17
2024 12
2025 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

309 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
Drug screening on digital microfluidics for cancer precision medicine.
Zhai J, Liu Y, Ji W, Huang X, Wang P, Li Y, Li H, Wong AH, Zhou X, Chen P, Wang L, Yang N, Chen C, Chen H, Mak PI, Deng CX, Martins R, Yang M, Ho TY, Yi S, Yao H, Jia Y. Zhai J, et al. Among authors: ho ty. Nat Commun. 2024 May 22;15(1):4363. doi: 10.1038/s41467-024-48616-3. Nat Commun. 2024. PMID: 38778087 Free PMC article.
Metronomic therapy for gynecologic cancers.
Su WH, Ho TY, Li YT, Lu CH, Lee WL, Wang PH. Su WH, et al. Among authors: ho ty. Taiwan J Obstet Gynecol. 2012 Jun;51(2):167-78. doi: 10.1016/j.tjog.2012.04.002. Taiwan J Obstet Gynecol. 2012. PMID: 22795090 Free article. Review.
Persistent Staphylococcus aureus bacteremia.
Huang PH, Chen NC, Ho TY, Chen CL. Huang PH, et al. Among authors: ho ty. Intern Med. 2015;54(5):541-2. doi: 10.2169/internalmedicine.54.3487. Epub 2015 Jan 15. Intern Med. 2015. PMID: 25758088 Free article. No abstract available.
Orbital arteriovenous malformation.
Ho TY, Wang AG, Lin MC, Yen MY. Ho TY, et al. Jpn J Ophthalmol. 2010 Nov;54(6):636-7. doi: 10.1007/s10384-010-0867-0. Epub 2010 Dec 30. Jpn J Ophthalmol. 2010. PMID: 21191733 No abstract available.
Application of transcriptomics in Chinese herbal medicine studies.
Lo HY, Li CC, Huang HC, Lin LJ, Hsiang CY, Ho TY. Lo HY, et al. Among authors: ho ty. J Tradit Complement Med. 2012 Apr;2(2):105-14. doi: 10.1016/s2225-4110(16)30083-9. J Tradit Complement Med. 2012. PMID: 24716122 Free PMC article. Review.
309 results